ATE349531T1 - Isolierung und charakterisierung des csa-operons (etec-cs4 pili) und verfahren zu dessen anwendung - Google Patents
Isolierung und charakterisierung des csa-operons (etec-cs4 pili) und verfahren zu dessen anwendungInfo
- Publication number
- ATE349531T1 ATE349531T1 AT01928715T AT01928715T ATE349531T1 AT E349531 T1 ATE349531 T1 AT E349531T1 AT 01928715 T AT01928715 T AT 01928715T AT 01928715 T AT01928715 T AT 01928715T AT E349531 T1 ATE349531 T1 AT E349531T1
- Authority
- AT
- Austria
- Prior art keywords
- csa operon
- etec
- pili
- characterization
- isolation
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000012512 characterization method Methods 0.000 title 1
- 238000002955 isolation Methods 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19862600P | 2000-04-20 | 2000-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE349531T1 true ATE349531T1 (de) | 2007-01-15 |
Family
ID=32849273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01928715T ATE349531T1 (de) | 2000-04-20 | 2001-04-20 | Isolierung und charakterisierung des csa-operons (etec-cs4 pili) und verfahren zu dessen anwendung |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6902736B2 (de) |
| EP (1) | EP1280912B1 (de) |
| AT (1) | ATE349531T1 (de) |
| AU (2) | AU5554301A (de) |
| CA (1) | CA2407523A1 (de) |
| CZ (1) | CZ20023795A3 (de) |
| DE (1) | DE60125528T2 (de) |
| ES (1) | ES2276785T3 (de) |
| HU (1) | HUP0300297A3 (de) |
| MX (1) | MXPA02010407A (de) |
| NO (1) | NO20025146L (de) |
| NZ (1) | NZ522272A (de) |
| PL (1) | PL359293A1 (de) |
| WO (1) | WO2001081582A2 (de) |
| ZA (1) | ZA200209042B (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7527802B2 (en) * | 2001-02-13 | 2009-05-05 | The United States Of America As Represented By The Secretary Of The Army | Vaccine for transcutaneous immunization |
| GB0121998D0 (en) * | 2001-09-11 | 2001-10-31 | Acambis Res Ltd | Attenuated bacteria useful in vaccines |
| AU2002365374A1 (en) * | 2001-11-28 | 2003-06-10 | Angiogenetics Sweden Ab | Regulation of hypoxia-inducible gene expression with antisense inhibitory pas domain protein |
| ATE373077T1 (de) * | 2002-02-25 | 2007-09-15 | Us Army Medical Res & Materiel | Verfahren zur herstellung von cs6- antigenimpfstoff zur behandlung, vorbeugung oder hemmung enterotoxigener escherichia coli- infektionen |
| EP2471549A1 (de) | 2005-01-11 | 2012-07-04 | The United States of America as represented by The Secretary of The Navy | Adhäsin als Immunogen gegen Escherichia coli |
| WO2007117339A2 (en) * | 2006-01-11 | 2007-10-18 | The United States Of America As Respresented By The Secretary Of The Navy | Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli |
| CA2726293C (en) * | 2008-06-03 | 2017-02-28 | University Of Maryland, Baltimore | Non-hemolytic clya for excretion of proteins |
| US9452205B2 (en) * | 2012-09-24 | 2016-09-27 | Montana State University | Recombinant Lactococcus lactis expressing Escherichia coli colonization factor antigen I (CFA/I) fimbriae and their methods of use |
| AU2013345316B2 (en) | 2012-11-19 | 2016-04-14 | The United States Of America As Represented By The Secretary Of The Navy | Recombinant polypeptide construct comprising multiple enterotoxigenic Escherichia coli fimbrial subunits |
| US10500261B2 (en) | 2014-11-05 | 2019-12-10 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic antigen constructs against campylobacter jejuni |
| EP3215226A4 (de) | 2014-11-05 | 2018-05-30 | The United States Of America As Represented By The Secretary Of The Navy | Synthetische antigenkonstrukte gegen campylobacter jejuni |
| CN117051021B (zh) * | 2023-08-01 | 2024-09-20 | 扬州大学 | 非诱导型表达鸡白痢沙门菌Bcf菌毛的鸡伤寒沙门菌重组菌及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5417986A (en) * | 1984-03-16 | 1995-05-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE287703T1 (de) * | 1995-04-14 | 2005-02-15 | Nektar Therapeutics | Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit |
| US5914114A (en) | 1995-06-02 | 1999-06-22 | The United States Of America As Represented By The Secretary Of The Army | Method of raising antibodies against E. coli of the family CS4-CFA/I |
| US5932715A (en) * | 1995-06-07 | 1999-08-03 | Emory University | Nucleotide sequences encoding a CS2 pilin protein |
| US6110898A (en) * | 1996-05-24 | 2000-08-29 | University Of Maryland, Baltimore | DNA vaccines for eliciting a mucosal immune response |
| US6190669B1 (en) * | 1998-05-13 | 2001-02-20 | University Of Maryland, Baltimore | Attenuated mutants of salmonella which constitutively express the Vi antigen |
-
2001
- 2001-04-20 CZ CZ20023795A patent/CZ20023795A3/cs unknown
- 2001-04-20 MX MXPA02010407A patent/MXPA02010407A/es active IP Right Grant
- 2001-04-20 CA CA002407523A patent/CA2407523A1/en not_active Abandoned
- 2001-04-20 ES ES01928715T patent/ES2276785T3/es not_active Expired - Lifetime
- 2001-04-20 AU AU5554301A patent/AU5554301A/xx active Pending
- 2001-04-20 NZ NZ522272A patent/NZ522272A/en unknown
- 2001-04-20 HU HU0300297A patent/HUP0300297A3/hu unknown
- 2001-04-20 AU AU2001255543A patent/AU2001255543B2/en not_active Ceased
- 2001-04-20 AT AT01928715T patent/ATE349531T1/de not_active IP Right Cessation
- 2001-04-20 WO PCT/US2001/012914 patent/WO2001081582A2/en active IP Right Grant
- 2001-04-20 DE DE60125528T patent/DE60125528T2/de not_active Expired - Lifetime
- 2001-04-20 EP EP01928715A patent/EP1280912B1/de not_active Expired - Lifetime
- 2001-04-20 PL PL01359293A patent/PL359293A1/xx not_active Application Discontinuation
- 2001-04-20 US US09/839,894 patent/US6902736B2/en not_active Expired - Lifetime
-
2002
- 2002-10-25 NO NO20025146A patent/NO20025146L/no not_active Application Discontinuation
- 2002-11-07 ZA ZA200209042A patent/ZA200209042B/en unknown
-
2005
- 2005-02-10 US US11/053,876 patent/US7399474B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2276785T3 (es) | 2007-07-01 |
| NO20025146L (no) | 2002-12-05 |
| US7399474B2 (en) | 2008-07-15 |
| DE60125528T2 (de) | 2007-10-11 |
| AU5554301A (en) | 2001-11-07 |
| CA2407523A1 (en) | 2001-11-01 |
| NO20025146D0 (no) | 2002-10-25 |
| MXPA02010407A (es) | 2003-05-23 |
| AU2001255543B2 (en) | 2005-06-23 |
| ZA200209042B (en) | 2004-03-08 |
| US6902736B2 (en) | 2005-06-07 |
| US20020176868A1 (en) | 2002-11-28 |
| US20050136070A1 (en) | 2005-06-23 |
| HUP0300297A2 (en) | 2003-05-28 |
| EP1280912B1 (de) | 2006-12-27 |
| CZ20023795A3 (cs) | 2003-04-16 |
| EP1280912A2 (de) | 2003-02-05 |
| PL359293A1 (en) | 2004-08-23 |
| DE60125528D1 (de) | 2007-02-08 |
| WO2001081582A2 (en) | 2001-11-01 |
| HUP0300297A3 (en) | 2005-09-28 |
| WO2001081582A3 (en) | 2002-05-02 |
| NZ522272A (en) | 2004-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1373296T3 (da) | Proteiner, der frembringer et ændret immunogent respons, og fremgangsmåder til fremstilling og anvendelse deraf | |
| WO2005016962A3 (en) | Compositions and methods for the treatment of immune related diseases | |
| WO2001034801A3 (en) | Recombinant gelatin in vaccines | |
| IL175021A0 (en) | Chromatin insulator, its preparation and use in protein expression | |
| WO2004043407A3 (en) | Methods and products for treating staphylococcal infections | |
| DE69929444D1 (de) | Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung | |
| EP1594536A4 (de) | Adjuvante influenza-vakzine | |
| ATE349531T1 (de) | Isolierung und charakterisierung des csa-operons (etec-cs4 pili) und verfahren zu dessen anwendung | |
| YU19903A (sh) | Novi receptor nukleinskih kiselina i polipeptida | |
| HUP0302965A2 (hu) | Vakcina | |
| FR21C1005I2 (fr) | Antigenes de streptococcus pyogenes et fragments d'adn correspondants | |
| ATE541036T1 (de) | Verfahren zur überexpression zwitterionischer polysaccharide | |
| SG146662A1 (en) | Method | |
| MXPA03007413A (es) | Composicion y metodo para tratar enfermedades inflamatorias. | |
| AU2002310474A1 (en) | Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same | |
| PT1290160E (pt) | Polipeptideos pellino humanos | |
| DK0892054T3 (da) | Clostridium perfringens-vaccine | |
| DK0811068T3 (da) | Humane DNase I varianter | |
| DE60126490D1 (de) | Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form | |
| WO2001066740A3 (en) | Compositions and methods for the treatment of immune related diseases | |
| DE60218463D1 (de) | Untereiheitsimpfstoffe und verfahren zur deren herstellung | |
| WO2002070699A3 (en) | Cofactors of the estrogen receptor alpha and methods of use | |
| WO2002022817A3 (en) | Nuclear receptor l66 and methods of use | |
| EP1331268A4 (de) | Neue proteine, diese kodierende gene und verfahren zu deren verwendung | |
| AU2001292273A1 (en) | Novel proteins, genes encoding them and method of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |